Table 1 Patient and tumour characteristics at diagnosis in all cohorts and according to skeletal mass index
Clinical and pathological parameters | Total | High SMI | Low SMI | P-value |
|---|---|---|---|---|
|  | n = 89 | n = 26 (29.1%) | n = 63 (70.7%) |  |
Age (years), median (range) | 66.0 (36.0–86.0) | 64.0 (36.0–78.0) | 67.0 (42.0–86.0) | 0.08 |
Sex | Â | Â | Â | Â |
Male/female | 73 (82.0)/16 (18.0) | 22 (15.4)/4 (84.6) | 51 (19.0)/12 (81.0) | 0.6 |
Smoking status | Â | Â | Â | 0.2 |
Yes | 33 (37.0) | 10 (38.5) | 23 (36.5) | |
No | 13 (14.6) | 6 (23.0) | 7 (11.1) | |
Ex-smoker | 43 (48.4) | 10 (38.5) | 33 (52.4) | |
Alcohol drinker | Â | Â | Â | 0.1 |
Yes | 29 (32.5) | 10 (38.5) | 19 (30.1) | |
No | 13 (14.6) | 6 (23.0) | 7 (11.1) | |
Ex-alcohol drinker | 47 (52.9) | 10 (38.5) | 37 (58.8) | |
Tumour histological subtype | Â | Â | Â | 0.03 |
Squamous cell carcinoma | 53 (59.6) | 11 (42.3) | 42 (66.6) | |
Adenocarcinoma | 36 (40.4) | 15 (57.7) | 21 (33.4) | |
Endobrachyoesophageal status | Â | Â | Â | 0.4 |
Yes/No | 13 (14.6)/76 (85.4) | 5 (19.2)/21 (80.8) | 8 (12.7)/55 (87.3) | |
TNM Stage | Â | Â | Â | 0.1 |
II | 42 (47.2) | 9 (34.6) | 33 (52.4) | |
III | 47 (52.8) | 17 (65.4) | 30 (47.6) | |
Tumour location | Â | Â | Â | 0.4 |
Upper | 20 (22.4) | 4 (15.4) | 16 (25.4) | |
Mean | 26 (29.3) | 6 (23.0) | 20 (31.7) | |
Lower | 38 (42.7) | 14 (53.9) | 24 (38.1) | |
More than two locations | 5 (5.6) | 2 (7.7) | 3 (4.8) | Â |
Performance status | Â | Â | Â | 0.006 |
0/1 | 74 (83.2) | 26 (100.0) | 48 (76.2) | |
2/3 | 15 (16.8) | 0 (0) | 15 (23.8) | |
Nutritional parameters | Â | Â | Â | Â |
BMI (kg/m2) before the cancer diagnosis | Â | Â | Â | Â |
Median (range) | 26.3 (17.0–52.9) | 28.8 (21.2–52.9) | 25.1 (17.0–37.6) | 0.0001 |
Underweight (< 18.5) | 1 (1.1) | 0 (0) | 1 (1.6) | 0.006 |
Normal (≥ 18.5 < 25.0) | 31 (34.8) | 3 (11.5) | 28 (44.4) | |
Overweight (≥ 25.0 < 30.0) | 18 (20.2) | 10 (38.5) | 8 (12.7) | |
Obese (≥ 30.0) | 39 (43.9) | 13 (50) | 26 (41.3) | |
NRI at cancer diagnosis | Â | Â | Â | 0.6 |
> 97.5 | 26 (29.2) | 7 (27.0) | 19 (30.2) | |
97.5–83.5 | 41 (46.0) | 11 (42.3) | 30 (47.6) | |
< 83.5 | 22 (24.8) | 8 (30.7) | 19 (22.2) | |
Albumin level (g/L) median (range) | 36.0 (17.5–48.0) | 35.5(22.0–43.0) | 36.2(17.5–48.0) | 0.3 |
 C-reactive protein, median (range) | 9.5(1.0–113.0) | 9.0(1.0–96.0) | 12(1.0–113.0) | 0.9 |
BMI (kg/m2) at cancer diagnosis | Â | Â | Â | Â |
Median (range) | 24.1 (14.9–47.7) | 27.9 (20.9–47.7) | 22.6(14.9–37.2) | < 0.0001 |
Underweight (< 18.5) | 10 (11.1) | 0 (0) | 10 (15.9) | 0.0008 |
Normal (≥ 18.5 < 25.0) | 40 (44.9) | 8 (30.7) | 32 (50.8) | |
Overweight (≥ 25.0 < 30.0) | 30 (33.8) | 11 (42.3) | 19 (30.2) | |
Obese (≥ 30.0) | 9 (10.1) | 7 (27.0) | 2 (3.1) | |
Weight loss (%) median (range) | 8.0 (– 1.2–38.7) | 6.5 (0–27.0) | 9.0 (– 1.2–38.7) | 0.2 |
Special nutritional management | Â | Â | Â | 0.4 |
Oral nutritional supplements | 19 (21.3) | 7 (27.0) | 12 (19.0) | |
Enteral nutrition | 66 (74.1) | 17 (65.3) | 49 (77.7) | |
Parenteral nutrition + enteral nutrition | 4 (4.5) | 2 (7.7) | 2 (3.1) | |
Current therapies, n (%) | Â | Â | Â | 0.3 |
Chemotherapy | 22 (24.7) | 8 (30.7) | 14 (22.2) | |
Radiotherapy | 10 (11.2) | 1 (3.9) | 9 (14.3) | |
Radiochemotherapy | 57 (64.1) | 17 (65.4) | 40 (63.5) | |
Surgery (yes) | 19 (21.4) | 8 (30.7) | 11 (17.4) | 0.1 |
Complications | 14 (73.6) | 6 (75.0) | 8 (72.7) | 0.9 |
Respiratory complications | 10 (52.6) | 5 (62.5) | 5 (45.4) | 0.4 |
Length of hospital stay (days) | 28.0 (14.0–60.0) | 24.0 (14.0–44.0) | 29.5 (19.0–60.0) | 0.4 |
Relapse | Â | Â | Â | 0.04 |
No | 42 (47.2) | 12 (46.1) | 30 (47.6) | |
Local relapse | 23 (25.8) | 3 (11.5) | 20 (31.7) | |
Metastatic relapse | 24 (27.0) | 11 (42.3) | 13 (20.6) |